Department of Pediatric Medicine, Hematology-Oncology
Texas Children's Hospital
6701 Fannin St.14th FloorHouston, TX 77030Get Map & Directions
Director, Bone Tumors Program and Leader, Musculoskeletal Tumor Clinic - Texas Children's Cancer Center
University of North Carolina at Chapel Hill, Doctor of Medicine, 1993
Children's Hospital of Los Angeles, Pediatrics, 1996
Baylor College of Medicine, Pediatric Hematology Oncology, 2001
Dr. Lisa Wang is a member of the Solid Tumor Team and has a special interest in sarcomas, particularly bone sarcomas (osteosarcoma, Ewing’s sarcoma). Dr. Lisa Wang is Director of the Osteosarcoma Program at Texas Children's Cancer Center which brings together clinical and basic science researchers investigating various aspects of OS biology and treatment, and actively promotes research and clinical educational activities for fellows and students centered around bone sarcomas. Dr. Lisa Wang is also the leader of the Musculoskeletal Tumor Clinic, an interdisciplinary clinic within the Texas Children's Cancer Center that brings together the orthopedic surgeon, pediatric oncologist, pediatric nurse practitioner, solid tumor fellow, social worker, and other caregivers to decide on management plans for patients with bone tumors. Dr. Lisa Wang is a member of the Children’s Oncology Group Bone Tumor Committee, and serve as the institutional P.I. for the current open cooperative group randomized clinical trial to treat newly diagnosed OS patients (EURAMOS protocol), as well as the protocol for newly diagnosed Ewing’s sarcoma patients (AEWS0031).
Dr. Lisa Wang’s research interest includes the molecular pathogenesis of osteosarcoma with specific focus on the RECQL4 pathway and Rothmund-Thomson syndrome, a rare inherited disorder that predisposes affected individuals to developing osteosarcoma . Research goals include understanding the molecular basis of this and related disorders and the mechanisms that predispose to cancer development, defining the clinical phenotype and appropriate medical management of these patients, and understanding the role of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development.
Clinical Special InterestsSarcomas, particularly bone sarcomas (osteosarcoma, Ewing’s sarcoma)
Research InterestsMolecular pathogenesis of osteosarcomaRothmund-Thomson syndromeRole of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development
Pappo, A.S., Russell, H.V., Kornguth, D.G., Nuchtern, J.G., & Wang, L.L. (2008). Ch. 50.2 Cancers of Childhood, Solid Tumors of Childhood. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th edition. (Eds. Vincent DeVita, Jr., Theodore S. Lawrence, Steven A. Rosenberg) Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008: 2043-2083.
Mehollin-Ray, AR, Kozinetz CA, Schlesinger AE, Guillerman RP, Wang LL. Radiographic Abnormalities and Genotype-Phenotype Correlation with RECQL4 Mutation Status in Rothmund-Thomson Syndrome. American Journal of Roentgenology 2008 Aug;191(2):W62-6.
Hicks MJ, Roth J, Kozinetz CA, Wang LL. Clinicopathologic Features of Osteosarcoma in Patients with Rothmund-Thomson Syndrome. Journal of Clinical Oncology 2007; 25:370-375.
Wang, LL. Biology of Osteogenic Sarcoma. Cancer Journal 2005; 11(4): 294-305.
Wang, LL, Chintagumpala, M, Gebhardt, M. Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology. In: UpToDate, Basow, D (Ed), UpToDate, Waltham, MA 2009. Available at http://www.uptodate.com.
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.